DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Epilepsy Market: Industry Analysis & Outlook (2017-2021)" report to their offering.
Epilepsy is a group of neurological diseases characterized by epileptic seizures. Epileptic seizures are episodes that can vary from brief and nearly undetectable to long periods of vigorous shaking. These episodes can result in physical injuries including occasionally broken bones.
Epilepsy is divided into four main types; idiopathic generalized epilepsy, idiopathic partial epilepsy, symptomatic generalized epilepsy and symptomatic partial epilepsy. The cause of epilepsy can be genetic, a result of other disorders such as tumor or brain injury and due to certain seizure triggers.
Epilepsy is treated via antiepileptic drugs, surgery in certain cases and several complementary therapies such as ketogenic diets or neural stimulation. Based upon the drug type, epilepsy market can be divided into three main categories; first generation drugs, second generation drugs and third generation drugs.
The global epilepsy market is driven by factors such as development of novel drugs, launch of new drugs in developing regions and prevalence of neural disorders such as meningitis and tumors. This growth is then further spearheaded by increasing healthcare expenses and rising disposable incomes. However, the market growth is hindered by tedious drug approval process, generic erosion and high cost of treatment. Trends such as companies focusing on developing effective therapies for refractory epilepsy and physicians demanding higher efficacy drugs are listed in this report.
The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: Novartis AG., Pfizer Inc., GlaxoSmithKline Plc. and UCB are being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global epilepsy drugs market along with the study of the regional markets.
- Increasing Healthcare Expenditure
- Rising Disposable Income
- Development of Novel Drugs
- Prevalence of Neurological Disease and Brain Infections
- Launch of New Drugs in Underpenetrated Developing Countries
- Physicians Desire Higher Efficacy Drugs
- Focus on Development of Therapeutics for Refractory Epilepsy
- Hasty Drug Approval Process
- Generic Erosion
- High Cost of Antiepileptic Drugs
- GlaxoSmithKline Plc.
- Novartis AG
- Pfizer Inc.
For more information about this report visit http://www.researchandmarkets.com/research/w22p4q/global_epilepsy